CORDIS - Forschungsergebnisse der EU
CORDIS

Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH (non-alcoholic steatohepatitis) transition to inform early prevention and treatment strategies

Projektbeschreibung

Biomarker für nichtalkoholische Fettlebererkrankung

Die nichtalkoholische Fettlebererkrankung ist eine komplexe Krankheit, die mit Fettansammlungen und Entzündungen in der Leber einhergeht. Sie gilt als schwer diagnostizier- und behandelbar, da die zugrunde liegenden molekularen Mechanismen immer noch unklar sind. Das EU-finanzierte Projekt halt-RONIN wird erkunden, wie gesunde Menschen zu von der nichtalkoholischen Fettlebererkrankung Betroffenen werden. Das Gemeinschaftsunternehmen wird In-vitro- und In-vivo-Modelle entwickeln sowie neben klinischen Patientendaten neue Biomarker und spezifische Zielmoleküle entdecken. Es wird erwartet, dass die Ergebnisse die Diagnose der nichtalkoholischen Fettlebererkrankung, die Entwicklung krankheitsmodifizierender Maßnahmen und von Präventionsleitlinien unterstützen werden.

Ziel

Non-alcoholic fatty liver disease (NAFLD) is a multifactorial chronic inflammatory disease that is prevalent in 1 of 4 individuals with a significant personal, socioeconomic and healthcare burden, especially at the later, more severe inflammatory stage of disease - non-alcoholic steatohepatitis (NASH). Despite the severe negative impact of the disease on society, NAFLD remains difficult to diagnose and treat. Additionally, the molecular mechanisms underlying the transition from health to fatty liver to NASH remain poorly understood due to the lack of models that faithfully reflect the complexity of human disease. Hence, Halt-RONIN aims to uncover the early triggers of disease initiation and complex mechanistic drivers of disease progression by implementing a systems biology approach with integrative disease modelling resulting in opportunities for the improvement of the existing detection methods, providing a blueprint to inform personalized intervention strategies and drug discovery for NAFLD. To achieve this goal, Halt-RONIN will combine experimental data from advanced in vitro and in vivo models with multimodal data from extensive human NAFLD cohorts and biobanks and use in silico machine learning approaches, to discover new biomarkers and molecular targets specific to each stage of the health-to-disease transition. By validating preclinical experimental findings with real-world data, RONIN will allow for the discovery of novel biomarkers and molecular targets that are specific to the individual patient’s pathology. Consequently, healthcare professionals will gain the tools and knowledge required to diagnose and establish guidelines for the prevention and treatment of inflammation-driven health to disease. As such, in the long-term RONIN will decrease the number of NAFL patients who progress into NASH and provide disease-modifying strategies to improve patient outcomes.

Koordinator

UNIVERSIDAD COMPLUTENSE DE MADRID
Netto-EU-Beitrag
€ 815 651,53
Adresse
AVENIDA DE SENECA 2
28040 Madrid
Spanien

Auf der Karte ansehen

Region
Comunidad de Madrid Comunidad de Madrid Madrid
Aktivitätstyp
Higher or Secondary Education Establishments
Links
Gesamtkosten
€ 815 651,53

Beteiligte (19)

Partner (3)